MOUNJARO 2 5MG KWIKPEN
Item requires a valid prescription
Manufactured By LILLY PRODUCTS
Composition TIRZEPATIDE 2 5MG
RS 11812.50
MRP RS 13125.00
(10% OFF)
Includes all taxes
Package SIZE
( 2.4ML )
100% Authentic
Products
Free
Shipping*
Products
Return Policy
Description:
Mounjaro 2.5mg KwikPen
Mounjaro 2.5mg KwikPen (Tirzepatide 2.5mg) is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist manufactured by Eli Lilly and Company, indicated for the management of Type 2 Diabetes Mellitus in adults as an adjunct to diet and exercise, and for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The 2.5mg KwikPen is the initiation dose, designed to improve tolerability during the first four weeks of therapy. Available from Shabbir Medical Hall at the best price in India, this genuine Eli Lilly prescription injection pen is available online with cold-chain compliant home delivery.
BENEFITS: Mounjaro's dual-receptor mechanism delivers clinically superior outcomes compared to single-receptor GLP-1 agonists. By simultaneously activating GIP and GLP-1 receptors, Tirzepatide enhances glucose-stimulated insulin secretion, suppresses glucagon, slows gastric emptying, and powerfully reduces appetite and caloric intake. Clinical trials (SURPASS programme) demonstrated HbA1c reductions of up to 2.58% and body weight reductions of up to 22.5% at higher maintenance doses — making it one of the most efficacious agents available for both diabetes and obesity. The once-weekly KwikPen format improves adherence and convenience.
USAGE OVERVIEW: Mounjaro 2.5mg is administered as a once-weekly subcutaneous injection into the abdomen, thigh, or upper arm. The 2.5mg starting dose is maintained for 4 weeks before dose escalation under physician guidance. It can be taken at any time of day, with or without food.
SAFETY OVERVIEW: The most common side effects are gastrointestinal — nausea, vomiting, diarrhoea, and constipation — typically occurring during initial dose escalation and resolving over time. Serious considerations include thyroid C-cell tumour risk (contraindicated in MTC/MEN2 history), pancreatitis, and hypoglycaemia risk when combined with insulin or sulphonylureas. Not returnable once delivered due to cold-chain temperature sensitivity.
Uses / Indications:
• Type 2 Diabetes Mellitus (T2DM): as an adjunct to diet and exercise to improve glycaemic control in adults — reduces HbA1c significantly as monotherapy or add-on therapy
• Chronic Weight Management: in adults with BMI ≥30 kg/m² (obesity), or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease)
ADDITIONAL / OFF-LABEL / EMERGING USES:
• Cardiovascular risk reduction: ongoing data from SURPASS-CVOT and SELECT trial derivatives show benefit in reducing MACE events
• Non-alcoholic steatohepatitis (NASH/MASLD): emerging evidence for hepatic fat reduction
• Polycystic Ovary Syndrome (PCOS) with insulin resistance and obesity — under specialist supervision
• Pre-diabetes / metabolic syndrome with obesity — physician-directed only
NOTE: Mounjaro is NOT indicated for:
• Type 1 Diabetes Mellitus
• Diabetic ketoacidosis
• Patients with personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Interactions / Warnings:
THYROID TUMOUR WARNING (BLACK BOX / CONTRAINDICATION): In rodent studies, Tirzepatide caused dose-dependent thyroid C-cell tumours (including medullary thyroid carcinoma). Mounjaro is CONTRAINDICATED in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Report any neck lump, dysphagia, hoarseness, or difficulty breathing immediately.
PANCREATITIS: Acute pancreatitis, including fatal cases, has been reported with GLP-1 receptor agonists. Discontinue Mounjaro immediately if pancreatitis is suspected (severe abdominal pain). Do NOT reinstate Mounjaro if pancreatitis is confirmed.
DIABETIC RETINOPATHY: Rapid improvement in glycaemic control has been associated with temporary worsening of diabetic retinopathy. Monitor patients with pre-existing retinopathy closely.
RENAL IMPAIRMENT: No dose adjustment required for mild-moderate impairment. Severe dehydration from GI side effects can worsen renal function — ensure adequate hydration.
HYPOGLYCAEMIA RISK: Mounjaro as monotherapy has low hypoglycaemia risk (glucose-dependent mechanism). Risk increases significantly when combined with insulin or sulphonylureas — proactive dose reduction of these agents should be discussed with your physician.
GALLBLADDER DISEASE: Rapid weight loss with Mounjaro may increase the risk of gallstone formation (cholelithiasis) and gallbladder disease. Report right upper abdominal pain, fever, or jaundice promptly.
DRIVING & MACHINERY: Dizziness may occur, particularly in patients on combination therapy with risk of hypoglycaemia. Assess personal response before driving.
ELDERLY USE (≥65 years): No overall difference in efficacy, but greater attention to hydration, renal function, and hypoglycaemia risk. Dose escalation should be cautious.
PAEDIATRIC USE: Safety and efficacy in children (<18 years) not established. Not recommended.
Pregnancy interaction:
• Tirzepatide is NOT recommended during pregnancy.
• Animal reproductive studies showed foetal harm at clinically relevant doses.
• Women of childbearing potential should use effective contraception during treatment.
• Due to the long half-life of Tirzepatide (~5 days, with effects lasting weeks), contraception should be continued for at least 1 month after stopping Mounjaro — many guidelines recommend 2 months.
• If pregnancy is confirmed during treatment, discontinue Mounjaro immediately and consult your endocrinologist and obstetrician.
• Uncontrolled blood sugar during pregnancy poses significant risks to both mother and baby; transition to appropriate diabetes management (e.g., insulin) under specialist guidance.
BREASTFEEDING:
• It is not known whether Tirzepatide passes into human breast milk.
• Breastfeeding is NOT recommended during treatment due to potential risk to the nursing infant.
• Discuss with your doctor the benefits and risks before deciding on breastfeeding versus continuing Mounjaro.
FERTILITY:
• No specific data on Tirzepatide and human fertility. Significant weight loss (common with Mounjaro) can affect reproductive hormones — inform your gynaecologist/endocrinologist.
DOCTOR CONSULTATION WARNING:
• Never stop Mounjaro without consulting your physician, particularly if used for blood sugar control — abrupt discontinuation may cause glycaemic deterioration.
Expert advice:
1. DOSE ESCALATION IS NON-NEGOTIABLE — DO NOT SKIP STEPS:
• The 2.5mg starting dose is designed exclusively for tolerability initiation — it is NOT a therapeutic dose. Never skip the 4-week step-up schedule. Rapid escalation dramatically increases GI side effects (nausea, vomiting, diarrhoea) and risks treatment abandonment. Each dose step must be maintained for at least 4 weeks before any upward adjustment.
2. MANAGE GI SIDE EFFECTS PROACTIVELY:
• GI side effects peak during the first 4–8 weeks of treatment and usually improve significantly with time. Advise patients to: eat smaller meals, avoid high-fat or spicy foods, eat slowly, stay upright after eating, and remain well hydrated. Anti-emetics (ondansetron, metoclopramide) may be used short-term under physician advice if nausea is severe.
3. BLOOD GLUCOSE MONITORING IS ESSENTIAL:
• Patients on insulin or sulphonylureas must increase blood glucose monitoring frequency, particularly after each dose escalation. Proactive dose reduction of insulin/sulphonylurea is commonly needed — do not wait for hypoglycaemic episodes before acting.
4. STRICT COLD-CHAIN COMPLIANCE:
• Mounjaro is a temperature-sensitive biological product. Always refrigerate at 2°C–8°C immediately upon receipt. If kept at room temperature, use within 21 days and do NOT return to refrigerator. Never expose to temperatures above 30°C or direct sunlight. Use an insulated cool bag when transporting. Inspect the pen solution before each dose.
5. PREGNANCY CONTRACEPTION COUNSELLING:
• Women of reproductive age must be counselled that Mounjaro is not safe in pregnancy and that oral contraceptive absorption may be temporarily impaired during dose escalation. Recommend back-up contraception (condoms, IUD) for 4 weeks after each dose increase. Continue contraception for at least 1 month after stopping Mounjaro.
MONITORING ADVICE:
• HbA1c: Check at 3 months after initiation and every 3–6 months during maintenance to assess glycaemic response
• Fasting blood glucose and self-monitoring (SMBG): Increased frequency when on concomitant insulin/sulphonylureas
• Body weight: Monthly measurement — document % total body weight loss trajectory
• Renal function (eGFR, creatinine): Baseline and if persistent vomiting/diarrhoea causes dehydration concern
• Thyroid monitoring: Not routinely required, but examine neck at each visit; report any new thyroid symptoms promptly
• Gallbladder: Abdominal ultrasound if symptomatic biliary disease suspected
• Lipid profile: 3–6 months after starting — Mounjaro typically improves lipid parameters
COMPLIANCE TIPS:
• Set a recurring weekly reminder (same day and time each week) for injection
• Keep a dose log on the pen itself (mark each of the 4 doses used)
• Store pen in its original carton in the refrigerator door shelf for easy access
• Carry your physician's prescription and a diabetes/obesity medication alert card
• Order next pen 1 week before current pen runs out to maintain uninterrupted therapy
• Note: Product is NOT returnable once delivered — order only confirmed quantities
SAFETY TIPS:
• Inspect pen before each use: clear/slightly yellow solution only; discard if cloudy, discoloured, or expired
• Never share a KwikPen — even with a new needle, sharing poses cross-contamination risk
• Rotate injection sites weekly to prevent skin nodule formation (lipodystrophy)
• Dispose of used needles in a puncture-resistant sharps container
• Carry fast-acting glucose (glucose tablets, juice) if on concomitant insulin/sulphonylureas
• Inform all treating doctors, dentists, and emergency personnel that you are on Tirzepatide
Side Effects:
• Nausea (most common; typically mild-moderate, transient)
• Vomiting
• Diarrhoea
• Constipation
• Decreased appetite and reduced food intake
• Abdominal pain, bloating, indigestion (dyspepsia)
• Injection site reactions: redness, bruising, itching, nodule formation
• Belching, flatulence
• Fatigue and asthenia (especially early in treatment)
SERIOUS SIDE EFFECTS (contact your doctor immediately):
• Pancreatitis: severe, persistent upper abdominal pain (may radiate to back), vomiting — discontinue and seek urgent medical review
• Hypoglycaemia: particularly when combined with insulin or sulphonylureas — sweating, tremor, rapid heartbeat, confusion
• Acute gallbladder disease: cholelithiasis (gallstones), cholecystitis — right upper abdominal pain, fever, jaundice
• Heart rate increase: persistent tachycardia has been reported
• Acute kidney injury: secondary to dehydration from vomiting/diarrhoea — reduced urine output, ankle swelling
• Severe allergic reactions / anaphylaxis: urticaria, angioedema, bronchospasm, collapse
EMERGENCY SIGNS — SEEK IMMEDIATE MEDICAL HELP:
• Severe, persistent abdominal pain (pancreatitis)
• Neck lump, difficulty swallowing, hoarseness (possible thyroid tumour)
• Swelling of face, lips, tongue, or throat; difficulty breathing (anaphylaxis)
• Signs of severe low blood sugar (confusion, seizures, unconsciousness)
How to use:
STARTING DOSE:
• 2.5mg subcutaneously ONCE WEEKLY for 4 weeks
• Purpose: tolerability initiation — the 2.5mg dose is not a therapeutic maintenance dose
DOSE ESCALATION (under physician guidance):
• After Week 4: increase to 5mg once weekly
• If needed, further escalation in 2.5mg increments every 4 weeks
• Available strengths: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg
• Maximum approved dose: 15mg once weekly
MISSED DOSE:
• If ≤4 days since missed dose: administer as soon as possible, then resume weekly schedule
• If >4 days since missed dose: skip the missed dose and continue with next scheduled dose
• Do not administer two doses within 3 days of each other
HOW TO INJECT:
• Route: Subcutaneous injection only — abdomen (avoiding 5 cm around navel), front/outer thigh, or upper outer arm
• Rotate injection sites weekly to prevent lipodystrophy
• Can be injected at any time of day, with or without food
• KwikPen delivers 4 doses (one per week) — keep track of doses used
INJECTION TECHNIQUE:
• 1. Wash hands thoroughly
• 2. Remove pen cap, check solution — should be clear to slightly yellow; do not use if cloudy, discoloured or with particles
• 3. Select injection site and clean skin with alcohol swab
• 4. Pinch skin, insert needle fully, press and hold button until dose counter returns to 0
• 5. Count to 5 before removing needle to ensure full dose delivery
• 6. Replace needle cap, dispose in sharps container
STORAGE:
• Refrigerate at 2°C–8°C in original carton. Do NOT freeze.
• Once at room temperature (≤30°C): use within 21 days; do NOT return to refrigerator
• Protect from light and heat
• Keep out of reach of children
• NOT returnable once delivered (temperature-sensitive cold-chain product)
How it works:
Mounjaro contains Tirzepatide, a novel synthetic peptide that is the first approved dual GIP/GLP-1 receptor agonist — a mechanism class not previously available in any other diabetes or obesity medication.
DUAL RECEPTOR ACTIVATION:
1. GIP RECEPTOR (GIPR) AGONISM:
• GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone released from intestinal K-cells after meals
• Tirzepatide's GIP agonism enhances meal-stimulated insulin secretion, improves insulin sensitivity in adipose tissue, and contributes to weight loss via central appetite suppression
• GIP receptor activation also reduces nausea — making Tirzepatide better tolerated than GLP-1-only agents
2. GLP-1 RECEPTOR (GLP-1R) AGONISM:
• GLP-1 (glucagon-like peptide-1) is released from intestinal L-cells post-meal
• Tirzepatide's GLP-1 agonism: suppresses glucagon secretion, slows gastric emptying (reduces post-meal glucose spikes), signals the hypothalamus to reduce appetite and increase satiety
• Results in significantly reduced caloric intake and prolonged fullness
NET CLINICAL EFFECTS:
• Glucose-dependent insulin release (low hypoglycaemia risk as monotherapy)
• HbA1c reduction of 1.87–2.58% (SURPASS programme)
• Body weight reduction of 15–22.5% at maintenance doses (SURMOUNT programme)
• Reduction in systolic blood pressure and improvement in lipid profile
• Superior efficacy vs semaglutide (GLP-1 only) demonstrated in SURPASS-2 trial
Faq for medicine:
A: No, Mounjaro is not insulin. It helps your body release its own insulin more effectively when blood sugar is high.
Q: How long does one 2.5mg KwikPen last?
A: Each KwikPen is designed to deliver four 2.5mg doses (one dose per week), covering a full 28-day treatment cycle.
Q: Can I use Mounjaro for weight loss if I don’t have diabetes?
A: While primarily for Type 2 Diabetes, Mounjaro (Tirzepatide) is widely prescribed for chronic weight management in adults with a high BMI. Consult your physician for eligibility.
Medicine interaction:
• Insulin & Insulin Secretagogues (Sulphonylureas, Glinides): Significantly increased risk of hypoglycaemia. Dose reduction of insulin or sulphonylurea is often required when initiating Tirzepatide. Monitor blood glucose closely.
• Oral Contraceptives: Tirzepatide slows gastric emptying — may transiently reduce absorption of oral medications, including oral contraceptives. Consider non-oral contraception or use back-up contraception for 4 weeks after each dose escalation.
• Warfarin / Oral Anticoagulants: Slowed gastric emptying may alter anticoagulant absorption. Monitor INR more frequently when initiating or adjusting Mounjaro.
• Other GLP-1 Receptor Agonists (e.g., Semaglutide, Liraglutide, Dulaglutide): Do NOT combine — additive GI side effects and increased hypoglycaemia risk. Not recommended concurrently.
• Thyroid Medications: No direct pharmacokinetic interaction documented, but Tirzepatide may affect thyroid C-cells (see Warnings).
• Metformin: Generally safe to combine — no clinically significant pharmacokinetic interaction. Commonly used as combination therapy for T2DM.
VACCINE INTERACTIONS:
• No clinically significant interactions with vaccines documented.
SUPPLEMENT INTERACTIONS:
• No major interactions. Always inform your doctor of all supplements, vitamins, and herbal products you take.
